Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

BJC reports·2026
Same author

Machine learning, whole genome sequencing, and Mendelian randomization support a role of CRP on COVID-19 severity.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

BJC reports·2026
Same author

A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors.

Journal of medicinal chemistry·2026
Same author

From comprehensive geriatric assessment to rapid bedside screening: comparing MPI and BRASS in predicting hospital outcomes in older adults - the S. Giovanni-Addolorata Hospital-SIGOT GRACE study.

BMC geriatrics·2026
Same author

Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis.

Molecular medicine (Cambridge, Mass.)·2026

Related Experiment Video

Updated: Jun 1, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Lessons from recent trials on hemodialysis.

Francesco Locatelli, Andrea Cavalli, Sara Maria Viganò

    Contributions to Nephrology
    |June 1, 2011
    PubMed
    Summary

    Starting hemodialysis (HD) early versus late showed no survival benefit. Frequent HD (6 times/week) improved cardiac health and hypertension but increased vascular access issues.

    Area of Science:

    • Nephrology
    • Cardiovascular Medicine
    • Clinical Trials

    Background:

    • Hemodialysis (HD) is a critical treatment for end-stage kidney disease, improving survival and uremic symptom relief.
    • Optimal timing and frequency of HD remain debated topics in managing chronic kidney disease (CKD) patients.
    • Evidence-based medicine relies on well-designed randomized controlled trials (RCTs) to guide clinical practice.

    Purpose of the Study:

    • To evaluate the impact of early versus late initiation of hemodialysis on patient outcomes.
    • To compare the effects of conventional (3x/week) versus frequent (6x/week) in-center hemodialysis.
    • To provide evidence-based insights for optimizing hemodialysis protocols and patient care.

    Main Methods:

    • The IDEAL trial: Randomized controlled trial comparing early versus late initiation of hemodialysis.

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
    07:11

    Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

    Published on: July 19, 2018

  • The FHN daily trial: Randomized controlled trial comparing conventional 3x/week versus frequent 6x/week in-center hemodialysis.
  • Analysis of patient mortality, morbidity, cardiac function, and secondary clinical outcomes.

    • Main Results:

    • The IDEAL trial found no significant difference in mortality or morbidity between early and late HD initiation, questioning GFR-based timing.
    • The FHN daily trial demonstrated improvements in left ventricular mass, physical health, hypertension, and hyperphosphatemia with frequent HD.
    • Frequent HD was associated with a higher incidence of vascular access interventions.

    Conclusions:

    • Initiating hemodialysis based solely on estimated GFR may not be optimal.
    • Frequent hemodialysis offers significant clinical benefits for CKD patients, despite increased vascular access complications.
    • These RCTs provide valuable data for refining hemodialysis strategies and improving patient outcomes.